MX2007003319A - Derivados heterociclicos y su uso como agentes terapeuticos. - Google Patents

Derivados heterociclicos y su uso como agentes terapeuticos.

Info

Publication number
MX2007003319A
MX2007003319A MX2007003319A MX2007003319A MX2007003319A MX 2007003319 A MX2007003319 A MX 2007003319A MX 2007003319 A MX2007003319 A MX 2007003319A MX 2007003319 A MX2007003319 A MX 2007003319A MX 2007003319 A MX2007003319 A MX 2007003319A
Authority
MX
Mexico
Prior art keywords
desaturase
coa
inhibiting human
pyridazine derivatives
human stearoyl
Prior art date
Application number
MX2007003319A
Other languages
English (en)
Spanish (es)
Inventor
Jian-Min Fu
Vishnumurthy Kodumuru
Rajender Kamboj
Zaihui Zhang
Serguei Sviridov
Sultan Chowdhury
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35985314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007003319(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MX2007003319A publication Critical patent/MX2007003319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2007003319A 2004-09-20 2005-09-20 Derivados heterociclicos y su uso como agentes terapeuticos. MX2007003319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61147204P 2004-09-20 2004-09-20
PCT/US2005/033820 WO2006034341A2 (en) 2004-09-20 2005-09-20 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase

Publications (1)

Publication Number Publication Date
MX2007003319A true MX2007003319A (es) 2007-06-05

Family

ID=35985314

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003319A MX2007003319A (es) 2004-09-20 2005-09-20 Derivados heterociclicos y su uso como agentes terapeuticos.

Country Status (11)

Country Link
US (1) US7829712B2 (US20070167479A1-20070719-C00034.png)
EP (2) EP2316458A1 (US20070167479A1-20070719-C00034.png)
JP (2) JP5149009B2 (US20070167479A1-20070719-C00034.png)
CN (1) CN101083992A (US20070167479A1-20070719-C00034.png)
AR (1) AR051094A1 (US20070167479A1-20070719-C00034.png)
AU (1) AU2005286731A1 (US20070167479A1-20070719-C00034.png)
BR (1) BRPI0515500A (US20070167479A1-20070719-C00034.png)
CA (1) CA2580845A1 (US20070167479A1-20070719-C00034.png)
MX (1) MX2007003319A (US20070167479A1-20070719-C00034.png)
TW (1) TW200626155A (US20070167479A1-20070719-C00034.png)
WO (1) WO2006034341A2 (US20070167479A1-20070719-C00034.png)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AR051095A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AU2005286790A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-CoA-desaturase (SCD)
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006055187A1 (en) 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
KR101464767B1 (ko) 2005-10-25 2014-11-24 칼립시스, 인코포레이티드 Ｐｐａｒ의 조절자의 염 및 대사질환을 치료하는 방법
EP1966183A4 (en) 2005-12-20 2010-12-29 Merck Frosst Canada Ltd HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
KR101124070B1 (ko) 2006-06-05 2012-04-12 제논 파마슈티칼스 인크. 유기 화합물
EP2032566A4 (en) * 2006-06-12 2009-07-08 Merck Frosst Canada Ltd AZETIDINE DERIVATIVES AS DELTA-9 DEATURASE STÉAROYL-COENZYME INHIBITORS
EP2086970B1 (en) 2006-08-24 2014-02-26 Novartis AG 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
PT2076508E (pt) 2006-10-18 2011-03-07 Pfizer Prod Inc Compostos de ureia de éter biarílico
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CN101563319B (zh) 2006-12-19 2012-09-05 弗·哈夫曼-拉罗切有限公司 杂芳基吡咯烷基和哌啶基甲酮衍生物
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
MX2009011415A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
WO2008157844A1 (en) * 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
GB0714129D0 (en) * 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
WO2009073973A1 (en) * 2007-12-11 2009-06-18 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR070429A1 (es) * 2008-02-20 2010-04-07 Xenon Pharmaceuticals Inc Derivados de 1,3 tiazol como inhibidores de estearoil - coa -desaturasa
CA2718993A1 (en) * 2008-03-20 2009-09-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
AU2009225441B2 (en) * 2008-03-20 2012-12-13 Forest Laboratories Holdings Limited Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
US8273900B2 (en) * 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010075356A1 (en) * 2008-12-23 2010-07-01 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
EP2398809B1 (en) 2009-02-17 2015-07-08 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
MX346801B (es) 2009-03-13 2017-03-31 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular.
CN102448951B (zh) 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR101850813B1 (ko) 2009-06-29 2018-04-20 아지오스 파마슈티컬스 아이엔씨. 치료용 화합물 및 조성물
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US9073882B2 (en) 2010-10-27 2015-07-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058134A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2651898B1 (en) 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
CA2822432C (en) 2010-12-21 2019-09-24 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CN103608016A (zh) 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
ME03074B (me) 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Akтivatori piruvat kinaze za upotrebu u terapiji
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103874493A (zh) 2011-08-19 2014-06-18 默沙东公司 肾外髓质钾通道的抑制剂
US9527830B2 (en) 2011-09-16 2016-12-27 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
EP2771004B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN106220572B (zh) 2011-10-28 2019-12-13 因西必泰克新有限公司 哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法
US9108947B2 (en) 2011-10-31 2015-08-18 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
WO2013066718A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773199B1 (en) 2011-10-31 2019-04-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
WO2013085954A1 (en) * 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
WO2013085957A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors
WO2013090271A1 (en) 2011-12-16 2013-06-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
KR20150013777A (ko) 2012-05-22 2015-02-05 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘, 엘티디. 미분화세포의 선택적 억제제
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
EP2925322B1 (en) 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
MX2015006754A (es) * 2012-12-03 2015-08-05 Hoffmann La Roche Compuestos de amida de isoxazol sustituido.
EP2934533B1 (en) 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
PE20160122A1 (es) 2013-03-13 2016-02-12 Forma Therapeutics Inc Compuestos nobles y composiciones para la inhibicion de fasn
WO2014150132A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA030631B1 (ru) 2013-07-31 2018-09-28 Новартис Аг 1,4-дизамещенные аналоги пиридазинхинолина и способы лечения состояний, связанных с smn-дефицитом
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
GB201420095D0 (en) 2014-11-12 2014-12-24 Takeda Pharmaceutical New use
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
JP7320339B2 (ja) 2015-06-11 2023-08-03 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化因子を使用する方法
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) * 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
KR20180067658A (ko) 2015-10-15 2018-06-20 아지오스 파마슈티컬스 아이엔씨. 악성 종양의 치료를 위한 조합물 요법
MX2018004587A (es) 2015-10-15 2018-08-14 Agios Pharmaceuticals Inc Terapia de combinacion para tratar tumores malignos.
BR112018008431A2 (pt) 2015-11-02 2018-11-06 Janssen Pharmaceutica Nv composto de [1,2,4]triazolo[1,5-a]pirimidin-7-il
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
SG11201903892UA (en) 2016-11-02 2019-05-30 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
AU2017353313C1 (en) 2016-11-02 2022-06-09 Janssen Pharmaceutica Nv (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
ES2855032T3 (es) 2016-11-02 2021-09-23 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
BR112019013954A2 (pt) 2017-01-06 2020-02-11 Yumanity Therapeutics, Inc. Métodos para o tratamento de distúrbios neurológicos
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
WO2019133813A1 (en) * 2017-12-29 2019-07-04 Orfan Biotech Inc. Glycolate oxidase inhibitors and use thereof
JP7305658B2 (ja) 2018-01-31 2023-07-10 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン
WO2019206828A1 (en) 2018-04-23 2019-10-31 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against rsv
MA52365A (fr) 2018-04-25 2021-03-03 Yumanity Therapeutics Inc Composés et leurs utilisations
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
SG11202012930RA (en) 2018-07-06 2021-01-28 Orfan Biotech Inc Triazole glycolate oxidase inhibitors
EP3829716B1 (en) * 2018-07-31 2023-02-01 Eli Lilly and Company 5-methyl-4-fluoro-thiazol-2-yl compounds
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
KR20220007845A (ko) * 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
CA3228553A1 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors
EP4387965A2 (en) 2021-08-18 2024-06-26 ChemoCentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors

Family Cites Families (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
US3830924A (en) * 1966-12-23 1974-08-20 American Cyanamid Co Substituted nitroimidazolyl-thiadiazoles as growth promoting agents
AT340933B (de) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
DE2427943C2 (de) 1974-06-10 1984-08-02 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2516040C2 (de) 1974-06-10 1984-12-20 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
NL171985C (nl) 1976-02-10 1983-06-16 Rhone Poulenc Ind Werkwijze voor het bereiden van preparaten met werking tegen schistosomiasis, de aldus verkregen gevormde preparaten en werkwijze voor het bereiden van 1,2-dithioolverbindingen.
ATE3294T1 (de) 1978-10-02 1983-05-15 Gruppo Lepetit S.P.A. 6-aminosubstituierte n-pyrrolyl-3-pyridazinamine, deren herstellung und sie enthaltende pharmazeutische antihypertensive zusammensetzungen.
US4247551A (en) * 1979-09-17 1981-01-27 Gruppo Lepetit S.P.A. N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents
FI70411C (fi) 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
CH655103A5 (de) 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
ATE77817T1 (de) 1985-04-30 1992-07-15 Dresden Arzneimittel 3-cyan-pyridine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
DE3536030A1 (de) 1985-10-09 1987-04-09 Thomae Gmbh Dr K Verwendung von benzimidazolen zur behandlung der migraene
AU1704588A (en) 1987-04-03 1988-11-02 Upjohn Company, The Amino-9,10-secosteroids
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
DE3827599A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Verwendung von optisch aktiven tetrahydrofuran-2-carbonsaeureestern als dotierstoffe in fluessigkristallmischungen, diese enthaltende fluessigkristallmischungen und neue optisch aktive tetrahydrofuran-2-carbonsaeureester
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
RU2099335C1 (ru) 1989-12-28 1997-12-20 Дзе Апджон Компани Диароматические соединения
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5166147A (en) * 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity
EP0471201A1 (de) * 1990-07-21 1992-02-19 Hoechst Aktiengesellschaft Neue Oxazolidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
DE4031000A1 (de) 1990-10-01 1992-04-09 Hoechst Ag 4- oder 5-substituierte pyridin-2-carbonsaeuren, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
EP0520292A1 (de) * 1991-06-19 1992-12-30 Hoechst Aktiengesellschaft Chirale Azetidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
WO1993001181A1 (en) 1991-07-03 1993-01-21 The Upjohn Company Substituted indoles as anti-aids pharmaceuticals
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9117639D0 (en) 1991-08-15 1991-10-02 Ici Plc Therapeutic compounds
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
AU3351293A (en) 1992-01-21 1993-08-03 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
EP0630370A1 (en) 1992-03-11 1994-12-28 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
DE4228792A1 (de) * 1992-08-29 1994-03-03 Hoechst Ag Pyridylaminopiperidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und deren Verwendung als Fungizide
IT1255704B (it) 1992-09-30 1995-11-10 Boehringer Mannheim Italia Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree
DE4236106A1 (de) * 1992-10-26 1994-04-28 Hoechst Ag Azaaromatische Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung in flüssigkristallinen Mischungen
US5494908A (en) 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
US5380726A (en) 1993-01-15 1995-01-10 Ciba-Geigy Corporation Substituted dialkylthio ethers
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP3377826B2 (ja) 1993-05-06 2003-02-17 ヘキスト・アクチェンゲゼルシャフト 液晶組成物に使用するための新規化合物
US5547605A (en) * 1993-12-15 1996-08-20 Hoechst Aktiengesellschaft 2-Aryloxytetrafluoropropionic esters, process for their preparation, and their use in liquid-crystalline mixtures
DE4343286A1 (de) 1993-12-17 1995-06-22 Hoechst Ag Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
DE19502178A1 (de) * 1994-01-27 1995-08-03 Hoechst Ag Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Vorprodukte zur Herstellung von Flüssigkristallen
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4423044A1 (de) 1994-07-01 1996-01-04 Hoechst Ag 1-(3-Alkyloxiran-2-yl)alkylester mesogener Carbonsäuren und ihre Verwendung in flüssigkristallinen Mischungen
US5607932A (en) 1994-07-12 1997-03-04 Janssen Pharmaceutica N.V. Heterocyclic derivatives of azolones
US5637592A (en) 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
US5571811A (en) * 1994-07-12 1996-11-05 Janssen Pharmaceutica N.V. Sulfonamide derivatives of azolones
US6107458A (en) 1994-10-07 2000-08-22 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
US5668148A (en) * 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
DE19517051A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag 1-Fluor-6,7-dihydro-5H-isochinolin-8-on-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517038A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag 1,8-Difluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517060A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag 1-Fluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517056A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag 1-Fluor-5,6,7,8-tetrahydroisochinolin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517025A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag Trifluortetrahydroisochinolin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
ZA969622B (en) 1995-12-13 1998-05-15 Upjohn Co Oxazolidinone antibacterial agents having a six-membered heteroaromatic ring.
EP0876366B1 (en) 1996-01-15 2001-07-25 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US6313127B1 (en) * 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
GB9614238D0 (en) * 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DE19630068A1 (de) 1996-07-25 1998-01-29 Basf Ag Neue flüssigkristalline Verbindungen und deren Vorprodukte
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
DE59707681D1 (de) * 1996-10-28 2002-08-14 Rolic Ag Zug Vernetzbare, photoaktive Silanderivate
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
WO1999000386A1 (en) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
CN1239570A (zh) 1997-07-17 1999-12-22 索尼公司 磁记录介质和使用该介质的磁记录/再现装置
ES2125206B1 (es) * 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
SE9703377D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
HU226859B1 (en) 1997-10-27 2009-12-28 Neurosearch As Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them
AU1692399A (en) 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Aromatic compounds having cyclic amino or salts thereof
NZ506292A (en) 1998-02-13 2003-05-30 Upjohn Co Substituted aminophenyl isoxazoline methylamide derivatives useful as antimicrobials
JP2002504550A (ja) 1998-02-25 2002-02-12 ファルマシア・アンド・アップジョン・カンパニー 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体
ATE229945T1 (de) * 1998-03-19 2003-01-15 Upjohn Co Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole
CN1297441A (zh) 1998-04-20 2001-05-30 Basf公司 用作为钙蛋白酶抑制剂的杂环取代酰胺
US6500956B1 (en) 1998-04-29 2002-12-31 Axiva Gmbh Method for the catalytic production of substituted bipyridyl derivatives
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
GB9812019D0 (en) 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
IL140084A0 (en) 1998-06-05 2002-02-10 Astra Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
TR200100300T2 (tr) * 1998-08-04 2001-07-23 Astrazeneca Ab Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
ES2226427T3 (es) * 1998-08-25 2005-03-16 Ortho-Mcneil Pharmaceutical, Inc. Esteres y tioeteres de piridillo como agonistas de receptor de acetilcolina nicotinico y aplicacion terapeutica.
EP1119568B1 (en) 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
US6627630B1 (en) * 1998-10-21 2003-09-30 Takeda Chemical Industries, Ltd. Condensed pyridazine derivatives, their production and use
AU1455500A (en) 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
EP1135129A1 (en) 1998-12-02 2001-09-26 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
EP1156045A4 (en) 1999-01-28 2002-04-17 Nippon Shinyaku Co Ltd AMID DERIVATIVES AND DRUG COMPOSITIONS
EP1147112B1 (en) 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
PT1394150E (pt) 1999-02-24 2011-02-17 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
JP4820488B2 (ja) 1999-03-12 2011-11-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬として有用な化合物
ATE329596T1 (de) * 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AU779550B2 (en) 1999-04-09 2005-01-27 Meiji Seika Kaisha Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
DE19922723A1 (de) 1999-05-18 2000-11-23 Clariant Gmbh Aktivmatrix-Displays mit hohem Kontrast
AU5020400A (en) 1999-05-20 2000-12-12 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
US6127382A (en) 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
JP2003508509A (ja) 1999-09-04 2003-03-04 アストラゼネカ アクチボラグ ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
TR200201413T2 (tr) 1999-09-17 2003-02-21 Millennium Pharmaceuticals, Inc. Faktör Xa' nın inhibitörleri.
IL148801A0 (en) 1999-09-24 2002-09-12 Janssen Pharmaceutica Nv Antiviral compositions
US6677452B1 (en) * 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
EP1226123A1 (en) 1999-11-03 2002-07-31 Du Pont Pharmaceuticals Company Cyano compounds as factor xa inhibitors
AU1887401A (en) 1999-12-14 2001-06-25 Nippon Shinyaku Co. Ltd. Medicinal composition
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
US6518285B2 (en) * 1999-12-21 2003-02-11 Ortho Mcneil Pharmaceutical, Inc. Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials
WO2001047921A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
WO2001060458A2 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP2172560A3 (en) * 2000-02-24 2010-09-29 Xenon Pharmaceuticals Inc. stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
EP1261327B1 (en) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
WO2001064646A2 (en) 2000-03-01 2001-09-07 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
EP1339702A1 (en) * 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
AU2001247372A1 (en) 2000-03-15 2001-09-24 Warner Lambert Company 5-amide substituted diarylamines as mex inhibitors
US6613917B1 (en) 2000-03-23 2003-09-02 Allergan, Inc. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
EP1277729A4 (en) 2000-04-28 2005-05-11 Sankyo Co MODULATORS OF PPAR (GAMMA)
CN1657523A (zh) 2000-04-28 2005-08-24 田边制药株式会社 环状化合物
GB0010757D0 (en) * 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
WO2002010154A2 (en) * 2000-07-27 2002-02-07 Eli Lilly And Company Substituted heterocyclic amides
CN1446218A (zh) * 2000-08-08 2003-10-01 圣诺菲-合成实验室公司 苯并咪唑衍生物,它们的制备方法以及它们的治疗应用
EP1184442A1 (en) 2000-08-30 2002-03-06 Clariant International Ltd. Liquid crystal mixture
DE60134995D1 (de) 2000-09-26 2008-09-04 Xenon Pharmaceuticals Inc Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
ES2269467T3 (es) 2000-10-13 2007-04-01 Neurosearch A/S Tratamiento de transtornos afectivos por la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergenica.
DE60118241T2 (de) 2000-10-17 2006-12-28 Pharmacia & Upjohn Co. Llc, Kalamazoo Verfahren zur herstellung von oxazolidinonverbindungen
DE10060412A1 (de) * 2000-12-05 2002-06-06 Bayer Ag DELTA1-Pyrroline
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US20040077654A1 (en) 2001-01-15 2004-04-22 Bouillot Anne Marie Jeanne Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
EP1353915A2 (en) 2001-01-16 2003-10-22 AstraZeneca AB Therapeutic chroman compounds
IL156595A0 (en) 2001-01-16 2004-01-04 Astrazeneca Ab Therapeutic heterocyclic compounds
JP2004517129A (ja) 2001-01-16 2004-06-10 アストラゼネカ・アクチエボラーグ 治療用クロモン化合物
DK1362039T3 (da) 2001-02-16 2006-05-08 Aventis Pharma Inc Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin D3-receptorligander
US7126003B2 (en) 2001-03-07 2006-10-24 Daiichi Pharmaceutical Co., Ltd. Method for producing 2-azetidinone derivative
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2002074750A1 (en) * 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
PT1373218E (pt) * 2001-03-29 2008-02-21 Ortho Mcneil Janssen Pharm Derivados de imidazolilo úteis como ligandos do receptor h3 de histamina
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
MY149050A (en) 2001-04-16 2013-07-15 Merck Sharp & Dohme 3,4 di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US6911447B2 (en) * 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
BR0209499A (pt) 2001-05-09 2004-07-06 Sumitomo Chem Takeda Agro Co Composto, processo para produzir o composto, e, composição pesticida
PL367205A1 (en) 2001-06-15 2005-02-21 Yamanouchi Pharmaceutical Co, Ltd. Phenylpyridine carbonyl piperazine derivative
WO2003003008A1 (en) * 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
WO2003011843A1 (en) * 2001-08-03 2003-02-13 Novo Nordisk A/S Novel 2,4-diaminothiazole derivatives
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP1430033A4 (en) 2001-08-31 2004-12-15 Univ Northwestern PROTEIN KINASE ANTI-INFLAMMATORY AND INHIBITOR COMPOSITION AND METHOD OF USE
AU2002323475B2 (en) 2001-09-13 2006-09-28 Synta Pharmaceuticals Corp 2-aroylimidazole compounds for treating cancer
FR2829926B1 (fr) * 2001-09-26 2004-10-01 Oreal Composition pour la teinture des fibres keratiniques comprenant un colorant diazoique dicationique particulier
US6916812B2 (en) * 2001-10-09 2005-07-12 Bristol-Myers Squibb Company Alpha-aminoamide derivatives as melanocortin agonists
US6824707B2 (en) * 2001-10-23 2004-11-30 Clariant International Ltd. Active matrix liquid crystal device and smectic liquid crystal mixture
WO2003035602A1 (fr) 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
JPWO2003037862A1 (ja) 2001-10-30 2005-02-17 日本新薬株式会社 アミド誘導体及び医薬
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
GB0127008D0 (en) 2001-11-09 2002-01-02 Novartis Ag Organic compounds
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
AU2002344567A1 (en) 2001-11-28 2003-06-10 Daiso Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
WO2003048140A1 (fr) 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
AU2002350172A1 (en) 2001-12-07 2003-06-23 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
US20050119251A1 (en) 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US20030166932A1 (en) 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
EP1474401A2 (en) 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
PL213783B1 (pl) 2002-03-13 2013-05-31 Janssen Pharmaceutica Nv Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
US7205304B2 (en) 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
ATE396971T1 (de) 2002-03-13 2008-06-15 Janssen Pharmaceutica Nv Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
ES2306858T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas.
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AU2003220184A1 (en) 2002-03-20 2003-10-08 Schering Aktiengesellschaft Substituted piperazine antithrombotic pai-1 inhibitors
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
AU2003221786A1 (en) 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004009587A1 (en) 2002-07-22 2004-01-29 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
WO2004010927A2 (en) 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
CN1310918C (zh) 2002-09-04 2007-04-18 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EP1551406A1 (en) 2002-09-06 2005-07-13 Janssen Pharmaceutica N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment of allergic rhinitis
CN1681810A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的噁唑和噻唑化合物
WO2004026865A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
MXPA05003948A (es) 2002-10-17 2005-06-17 Amgen Inc Derivados de bencimidazol y su uso como ligandos de receptor vaniloide.
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20040097492A1 (en) 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE10254875A1 (de) 2002-11-25 2004-06-03 Bayer Healthcare Ag Phenylsulfoxid und -sulfon-Derivate
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
DE10259382A1 (de) 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
PL377847A1 (pl) 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US20050130989A1 (en) * 2003-01-28 2005-06-16 Aventis Pharma S. A. N-arylheteroaromatic products compositions containing them and use thereof
JP2007527363A (ja) 2003-02-03 2007-09-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バニロイドｖｒ１受容体のモジュレーターであるキノリン誘導アミド
GB0302671D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
EA010379B1 (ru) 2003-02-07 2008-08-29 Янссен Фармацевтика Н.В. Ингибирующие вич 1,2,4-триазины
CA2513527C (en) 2003-02-07 2012-08-14 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of hiv infection
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
EP1594842A1 (en) 2003-02-22 2005-11-16 MERCK PATENT GmbH Cyanopyridone derivatives as liquid crystals
EP1606282B1 (en) 2003-02-24 2008-11-12 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpipereidinye-derivatives as modulators of glucose metabolism
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2004078716A1 (en) 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
DE10322408A1 (de) 2003-05-16 2004-12-02 Degussa Ag Stickstoffhaltige monodentate Phosphine und deren Verwendung in der Katalyse
AR044586A1 (es) * 2003-06-04 2005-09-21 Aventis Pharma Sa Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004114118A1 (ja) 2003-06-23 2004-12-29 Sharp Kabushiki Kaisha 情報処理装置、集線装置、集線装置を備えたネットワーク情報処理システム、情報処理プログラムおよび記録媒体
US7595316B2 (en) * 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
WO2005003087A2 (en) 2003-07-01 2005-01-13 Orchid Chemicals And Pharmaceuticals Ltd. Oxazole derivatives as antibacterial agents
JP2007526894A (ja) 2003-07-16 2007-09-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グリコーゲンシンターゼキナーゼ３インヒビターとしてのトリアゾロピリミジン誘導体
NZ545058A (en) 2003-07-16 2008-05-30 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
US20070161637A1 (en) 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
AR045134A1 (es) 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
AU2004259263B2 (en) 2003-07-29 2010-12-16 High Point Pharmaceuticals, Llc Pyridazinyl- piperazines and their use as histamine H3 receptor ligands
ES2386354T3 (es) * 2003-07-29 2012-08-17 Xenon Pharmaceuticals Inc. Derivados de piridilo y su uso como agentes terapéuticos
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
BRPI0412343A (pt) 2003-07-30 2006-09-05 Xenon Pharmaceuticals Inc derivados de piridazina e seu uso como agentes terapêuticos
WO2005011656A2 (en) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
ES2568769T3 (es) * 2003-07-30 2016-05-04 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos
ATE532772T1 (de) * 2003-07-30 2011-11-15 Xenon Pharmaceuticals Inc Piperazinderivate und deren verwendung als therapeutische mittel
MXPA06001665A (es) * 2003-08-11 2006-04-28 Hoffmann La Roche Piperazina con grupo fenilo sustituido -or y su uso como inhibidores del transportador de glicina 1 (glyt-1).
WO2005014593A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Thiazole derivatives as npy antagonists
JP4866610B2 (ja) 2003-08-18 2012-02-01 富士フイルムファインケミカルズ株式会社 ピリジルテトラヒドロピリジン類およびピリジルピペリジン類
PL1658291T3 (pl) 2003-08-25 2014-03-31 Dogwood Pharmaceuticals Inc Podstawione 8-heteroaryloksantyny
EP1659123A1 (en) 2003-08-29 2006-05-24 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrazole derivative
KR100774621B1 (ko) * 2003-09-09 2007-11-14 에프. 호프만-라 로슈 아게 정신병 치료용의 글라이신 섭취 억제제로서의1-벤조일-피페라진 유도체
MXPA06002727A (es) 2003-09-09 2006-06-05 Hoffmann La Roche Derivados de 1-(2-amino-benzol)-piperazina como inhibidores de la captacion de glicina para el tratamiento de psicosis.
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
EA009734B1 (ru) 2003-09-25 2008-02-28 Янссен Фармацевтика Н.В. Производные пурина, ингибирующие репликацию вич
CA2537812C (en) 2003-09-26 2013-01-22 Exelixis, Inc. C-met modulators and method of use
AR047759A1 (es) 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US7807696B2 (en) 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
FR2860793A1 (fr) 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
BRPI0415851A (pt) 2003-10-24 2007-01-02 Solvay Pharm Gmbh utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
WO2005044192A2 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0327323D0 (en) 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
BRPI0417605B8 (pt) 2003-12-18 2021-05-25 Incyte Corp “n-[2-((3s)-3-{[4-hidróxi-4-(5-pirimidin-2- ilpiridin-2-il)ciclohexil]amino}-pirrolidin-1-il)-2- oxoetil]-3-(trifluor-metil)benzamida, ou um sal farmaceuticamente aceitável do mesmo e composição que o compreende”.
EP1701959A1 (en) 2003-12-22 2006-09-20 Pfizer Limited Triazole derivatives as vasopressin antagonists
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
AR048523A1 (es) * 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
AU2004321997A1 (en) 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
AU2005286790A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-CoA-desaturase (SCD)
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
CA2580856A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804799B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AR051095A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286793A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1902051A1 (en) 2005-06-09 2008-03-26 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Also Published As

Publication number Publication date
CN101083992A (zh) 2007-12-05
BRPI0515500A (pt) 2008-07-29
EP1814551A2 (en) 2007-08-08
US20080207587A1 (en) 2008-08-28
AU2005286731A1 (en) 2006-03-30
JP5149009B2 (ja) 2013-02-20
JP2013014623A (ja) 2013-01-24
US7829712B2 (en) 2010-11-09
WO2006034341A2 (en) 2006-03-30
WO2006034341A3 (en) 2006-05-18
JP2008513506A (ja) 2008-05-01
TW200626155A (en) 2006-08-01
EP2316458A1 (en) 2011-05-04
CA2580845A1 (en) 2006-03-30
AR051094A1 (es) 2006-12-20

Similar Documents

Publication Publication Date Title
MX2007003319A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
MX2007003330A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
MX2007003332A (es) Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
MX2007003325A (es) Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TNSN06034A1 (en) Pyridazine derivatives and their use as therapeutic agents
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
TW200638935A (en) Pyridazine derivatives and their use as therapeutic agents
IL173397A0 (en) Pyridyl derivatives and their use as therapeutic agents
TW200638945A (en) Combination therapy
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
MXPA05012466A (es) Derivados de quinolina como inhibidores de fosfodiesterasa.
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
MY144229A (en) Pyridazine derivatives and their use as therapeutic agents
ATE366720T1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
IL181666A0 (en) Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof
JO2829B1 (en) Pyridazine derivatives and their use as therapeutic agents
ATE337826T1 (de) Simplifizierte sarcodictyn-derivate als anti- tumor-mittel